| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
BRIEF COMMUNICATION |
IGF1 Gene Polymorphism and Risk for Hereditary Nonpolyposis Colorectal Cancer
Affiliations of authors: Department of Epidemiology (MZ, CIA, XG, IMC, JSJ, MLF), Department of GI Medicine and Nutrition (PML), Department of Surgical Oncology (MAR-B), University of Texas MD Anderson Cancer Center, Houston, TX
Correspondence to: Marsha L. Frazier, PhD, Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 189, Houston, TX 77030 (e-mail: mlfrazier{at}mdanderson.org).
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Insulin-like growth factor-I (IGF-I) is involved in colorectal carcinogenesis, and elevated plasma IGF-I levels are associated with sporadic colorectal cancer (CRC) risk. We investigated the relationship between IGF1 promoter cytosine-adenine (CA) dinucleotide–repeat polymorphism length and CRC risk in 121 MMR gene mutation carriers using Cox regression and Kaplan-Meier analysis. All statistical tests were two-sided. Time to onset for CRC increased for each decrease in CA-repeat number (median = 19 repeats, range = 12–22 repeats; hazard ratio [HR] = 1.17, 95% confidence interval [CI] = 1.05 to 1.31; P = .006). Patients carrying a CA
17 repeat allele had a statistically significantly higher CRC risk (HR = 2.36; 95% CI = 1.28 to 4.36; P = .006) than all others and were younger at onset (44 years versus 56.5 years; P = .023). These findings indicate a statistically significant association between shorter IGF1 CA-repeat lengths and increased risk for CRC in HNPCC. This is the first report, to our knowledge, to show that IGF1 variant genotypes modify risk of a hereditary form of cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: IGF-1 Gene Polymorphism and Risk for Hereditary Nonpolyposis Colorectal Cancer
- Stuart Reeves, Cliff Meldrum, and Rodney J. Scott
J Natl Cancer Inst 2006 98: 1664-1665.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease Endocr. Rev., October 1, 2009; 30(6): 586 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Milne, J. A. Royle, N. H. de Klerk, E. Blair, H. Bailey, C. Cole, J. Attia, R. J. Scott, and B. K. Armstrong Fetal Growth and Risk of Childhood Acute Lymphoblastic Leukemia: Results From an Australian Case-Control Study Am. J. Epidemiol., July 15, 2009; 170(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ryan and P. E. Goss The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer Oncologist, January 1, 2008; 13(1): 16 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Campbell, L. Edwards, J. R. McLaughlin, J. Green, H. B. Younghusband, and M. O. Woods Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland Clin. Cancer Res., July 1, 2007; 13(13): 3783 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Reeves, C. Meldrum, and R. J. Scott Re: IGF-1 Gene Polymorphism and Risk for Hereditary Nonpolyposis Colorectal Cancer. J Natl Cancer Inst, November 15, 2006; 98(22): 1664 - 1665. [Full Text] [PDF]
|
|